Related Experiment Video
Updated: Apr 16, 2026
08:58
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
13.1K
Biological therapy in acute severe ulcerative colitis: Indian experience
Tropical Gastroenterology : Official Journal of the Digestive Diseases Foundation
|March 5, 2015
Summary
Biological therapies offer rescue treatment for Ulcerative Colitis and Crohn's disease. Limited Indian data shows Infliximab use for severe Ulcerative Colitis, with other agents in trials.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Biological agents are established rescue therapies for steroid-refractory Ulcerative Colitis (UC) and Crohn's disease (CD).
- High costs and infection risks (e.g., tuberculosis) restrict biological use in developing nations.
- There is limited data on biological agent utilization in developing countries, specifically India.
Purpose of the Study:
- To report the limited Indian experience with available biological agents for inflammatory bowel disease (IBD).
- To describe the use of Infliximab as rescue therapy in severe refractory UC.
- To document the role of other biological agents within multicentre clinical trials in India.
Main Methods:
- Retrospective review of patients receiving biological therapy for IBD in India.
- Analysis of Infliximab usage as rescue therapy for severe, steroid-refractory UC.
- Inclusion of data on other biological agents used in multicentre clinical trials.
Main Results:
- Infliximab was utilized as a rescue therapy in severe refractory Ulcerative Colitis cases.
- Other biological agents were administered as part of multicentre clinical trials.
- This study provides initial insights into biological therapy use in the Indian IBD population.
Conclusions:
- Biological therapies, particularly Infliximab, have a role in managing severe refractory IBD in India.
- Further research is needed to assess the efficacy and safety of various biological agents in developing countries.
- Addressing cost and infection concerns is crucial for expanding biological therapy access in India.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
667
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
667
01:29Inflammatory Bowel Disease IV: Pharmacological Management
994
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
994
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
820
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
820
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
685
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
685
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
726
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
726
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
1.1K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.1K